Thioredoxin-1 and posttranslational modifications

Antioxidants and Redox Signaling

Volumn 8, Issue 9-10, 2006, Pages 1723-1728

  Haendeler, Judith ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; THIOREDOXIN; THIOREDOXIN 1; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CELL PROLIFERATION; HUMAN; NITROSYLATION; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW;

ANIMALS; CYSTEINE; GLUTATHIONE; HUMANS; NITRIC OXIDE; OXIDATION-REDUCTION; PROTEIN PROCESSING, POST-TRANSLATIONAL; S-NITROSOTHIOLS; THIOREDOXIN;

MAMMALIA;

EID: 33750915613     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2006.8.1723     Document Type: Review

References (56)

1. Akamatsu Y, Ohno T, Hirota K, Kagoshima H, Yodoi J, and Shigesada K. Redox regulation of the DNA binding activity in transcription factor PEBP2. The roles of two conserved cysteine residues. J Biol Chem 272: 14497-14500, 1997.
2. Berk BC, Abe JI, Min W, Surapisitchat J, and Van C. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann NY Acad Sci 947: 93-109; discussion 109-111, 2001.
3. Brigelius R, Lenzen R, and Sies H. Increase in hepatic mixed disulphide and glutathione disulphide levels elicited by paraquat. Biochem Pharmacol 31: 1637-1641, 1982.
4. Brigelius R, Muckel C, Akerboom TP, and Sies H. Identification and quantitation of glutathione in hepatic protein mixed disulfides and its relationship to glutathione disulfide. Biochem Pharmacol 32: 2529-2534, 1983.
5. Busse R and Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 33: 181-194, 1996.
6. Busse R and Fleming I. Pulsatile stretch and shear: physiological stimuli determining the production of endothelial-derived relaxing factor. J Vasc Res 35: 73-84, 1998.
7. Casagrande S, Bonetto V, Fratelli M, Gianazza E, Eberini I, Massignan T, Salmona M, Chang G, Holmgren A, and Ghezzi P. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci USA 99: 9745-9749, 2002.
8. Das KC. c-Jun NH2-terminal kinase-mediated redox-dependent degradation of IkappaB: role of thioredoxin in NF-kappaB activation. J Biol Chem 276: 4662-4670 Epub 2000 Nov 4663, 2001.
9. Edman JC, Ellis L, Blacher RW, Roth RA, and Rutter WJ. Sequence of protein disulphide isomerase and implications of its relationship to thioredoxin. Nature 317: 267-270, 1985.
10. Eklund H, Gleason FK, and Holmgren A. Structural and functional relations among thioredoxins of different species. Proteins 11: 13-28, 1991.
11. Forman-Kay JD, Clore GM, Wingfield PT, and Gronenborn AM. High-resolution three-dimensional structure of reduced recombinant human thioredoxin in solution. Biochemistry 30: 2685-2698, 1991.
12. Furchgott RF and Zawadzki JY. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376, 1980.
13. Furchgott RF and Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 3: 2007-2018, 1989.
14. Gasdaska JR, Kirkpatrick DL, Montfort W, Kuperus M, Hill SR, Berggren M, and Powis G. Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73→Ser mutation. Biochem Pharmacol 52: 1741-1747, 1996.
15. Gilbert HF. Redox control of enzyme activities by thiol/disulfide exchange. Methods Enzymol 107: 330-351, 1984.
16. Gilbert HF. Thiol/disulfide exchange equilibria and disulfide bond stability. Methods Enzymol 251: 8-28, 1995.
17. Haendeler J, Hoffmann J, Tischler V, Berk BC, Zeiher AM and Dimmeler S. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol 4: 743-749, 2002.
18. Haendeler J, Hoffmann J, Zeiher AM, and Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells. A novel vasculoprotective function of statins. Circulation 110: 856-861, 2004.
19. Hansen JM, Zhang H, and Jones DP. Differential oxidation of thioredoxin-1, thioredoxin-2, and glutathione by metal ions. Free Radic Biol Med 40: 138-145 Epub 2005 Oct 2019, 2006.
20. Harper R, Wu K, Chang MM, Yoneda K, Pan R, Reddy SP, and Wu R. Activation of nuclear factor-kappa b transcriptional activity in airway epithelial cells by thioredoxin but not by N-acetyl-cysteine and glutathione. Am J Respir Cell Mol Biol 25: 178-185, 2001.
21. Harrison D, Griendling KK, Landmesser U, Hornig B, and Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 91: 7A-11A, 2003.
22. Harrison DG. Endothelial dysfunction in atherosclerosis. Basic Res Cardiol 1: 87-102, 1994.
23. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 94: 3633-3638, 1997.
24. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, and Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem 274: 27891-27897, 1999.
25. Hoffmann J, Dimmeler S, and Haendeler J. Shear stress increases the amount of S-nitrosylated molecules in endothelial cells: Important role for signal transduction. FEBS Lett 551: 153-158, 2003.
26. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 264: 13963-13966, 1989.
27. Holmgren A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure 3: 239-243, 1995.
28. Holmgren A. Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid Redox Signal 2: 811-820, 2000.
29. Hwang CY, Ryu YS, Chung MS, Kim KD, Park SS, Chae SK, Chae HZ, and Kwon KS. Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1. Oncogene 23: 8868-8875, 2004.
30. Kosower NS and Kosower EM. Formation of disulfides with diamide. Methods Enzymol 143: 264-270, 1987.
31. Lane P, Hao G, and Gross SS. S-nitrosylation is emerging as a specific and fundamental posttranslational protein modification: head-to-head comparison with O-phosphorylation. Sci STKE 2001: RE1, 2001.
32. Liu H, Nishitoh H, Ichijo H, and Kyriakis JM. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol Cell Biol 20: 2198-2208, 2000.
33. Liu Y and Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 90: 1259-1266, 2002.
34. Martin JL. Thioredoxin-a fold for all reasons. Structure 3: 245-250, 1995.
35. Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J, and Taketo MM. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 178: 179-185, 1996.
36. Michelet L, Zaffagnini M, Marchand C, Collin y Decottignies P, Tsan P, Lancelin JM, Trost P, Miginiac-Maslow M, Noctor G, and Lemaire SD. Glutathionylation of chloroplast thioredoxin f is a redox signaling mechanism in plants. Proc Natl Acad Sci USA 102: 16478-16483 Epub 12005 Nov 16471,2005.
37. Miranda-Vizuete A, Ljung J, Damdimopoulos AE, Gustafsson JA, Oko R, Pelto-Huikko M, and Spyrou G. Characterization of Sptrx, a novel member of the thioredoxin family specifically expressed in human spermatozoa. J Biol Chem 276: 31567-31574, 2001.
38. Mitchell DA and Marietta MA. Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine. Nat Chem Biol 1: 154-158 Epub 2005 Jul 2010, 2005.
39. Moncada S and Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012, 1993.
40. Nerem RM, Harrison DG, Taylor WR, and Alexander RW. Hemodynamics and vascular endothelial biology. J Cardiovasc Pharmacol 21: S6-10, 1993.
41. Nordberg J and Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 31: 1287-1312, 2001.
42. Orr WC and Sohal RS. Extension of lifespan by overexpression of superoxide dismutase and catalase in Drosophila melanogaster. Science 263: 1128-1130, 1994.
43. Powis G and Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 30: 421-455, 2001.
44. Qin J, Clore GM, and Gronenborn AM. The high-resolution three-dimensional solution structures of the oxidized and reduced states of human thioredoxin. Structure 2: 503-522, 1994.
45. Ren X, Bjornstedt M, Shen B, Ericson ML, and Holmgren A. Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochemistry 32: 9701-9708, 1993.
46. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998.
47. Spyrou G, Enmark E, Miranda-Vizuete A, and Gustafsson J. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem 272: 2936-2941, 1997.
48. Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, Singel DJ, and Loscalzo J. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 89: 444-448, 1992.
49. Taniguchi Y, Taniguchi-Ueda Y, Mori K, and Yodoi J. A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. Nucleic Acids Res 24: 2746-2752, 1996.
50. Tao L, Gao E, Bryan NS, Qu Y, Liu HR, Hu A, Christopher TA, Lopez BL, Yodoi J, Koch WJ, Feelisch M, and Ma XL. Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci USA 101: 11471-11476 Epub 12004 Jul 11426, 2004.
51. Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, Powis G, and Jones DP. Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J Biol Chem 278: 33408-33415 Epub 32003 Jun 33419, 2003.
52. Wei SJ, Botero A, Hirota K, Bradbury CM, Markovina S, Laszlo A, Spitz DR, Goswami PC, Yodoi J, and Gius D. Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res 60: 6688-6695, 2000.
53. Weichsel A, Gasdaska JR, Powis G, and Montfort WR. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure 4: 735-751, 1996.
54. Wolin MS, Xie YW, and Hintze TH. Nitric oxide as a regulator of tissue oxygen consumption. Curr Opin Nephrol Hypertens 8: 97-103, 1999.
55. Yamanaka H, Maehira F, Oshiro M, Asato T, Yanagawa Y, Takei H, and Nakashima Y. A possible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast two-hybrid system. Biochem Biophys Res Commun 271: 796-800, 2000.
56. Yoshioka J, Schreiter ER, and Lee RT. Role of thioredoxin in cell growth through interactions with signaling molecules. Antioxid Redox Signal 2006 (in press).